The polyglutamine disease spinocerebellar ataxia type 17 (SCA17) is a neurodegenerative disease leading to severe neurological symptoms during development. Additionally, patients affected by SCA17 display psychosis earlier than their motor disorders.
Objective:
Here the putative psychotic phenotype and endophenotype of transgenic SCA17 rats was examined.
Methods:
The expression of schizophrenia-like symptoms was evaluated over a longitudinal period before and after the onset of neurological symptoms in SCA17. To this end, transgenic SCA17 rats’ monoamine neurotransmission was investigated along with their locomotion at baseline and in response to amphetamine using in-vivo microdialysis in free moving conditions, their sensorimotor gating using pre-pulse inhibition of startle reaction, and their object memory using the novel object recognition test as an index of cognitive impairments.
Results:
Presymptomatic SCA17 rats displayed dysregulated monoamine levels at baseline and in response to amphetamine compared with control wild-type (wt) rats. At that stage, neither amphetamine-induced hyperlocomotion nor sensorimotor gating differed from that in wt rats. Symptomatic SCA17 rats developed sensorimotor gating deficits and also showed an impaired object memory, while their monoaminergic responses remained supersensitive to amphetamine.
Conclusions:
The data of the present study demonstrate a neurochemical endophenotype in SCA17 rats resembling that of prodromal schizophrenia. These findings suggest that a sensitization of the monoamine systems arises early in adulthood in SCA17 rats and may predispose them to express schizophrenia-like symptoms later in life.
AmatoDCannevaFMaschauerS. (2013) A mechanism of antipsychotic treatment failure and its reversal. European Neuropsychopharmacology23 (Suppl. 2): S455.
3.
AmatoDMüllerCPCannevaF. (2014) Mechanisms of antipsychotic treatment failure. Abstract of the 4th Biennal Schizophrenia International Research Conference. Schizophrenia Research153(Suppl 69): S1–S384.
4.
AmatoDNatesanSKapurS. (2011a) Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. Behavioural Brain Research221: 311–313.
5.
AmatoDNatesanSYavichL. (2011b) Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. International Journal of Neuropsychopharmacoly14: 1327–1339.
6.
AmatoDPumMEGroosD. (2015) Neuropharmacology of light-induced locomotor activation. Neuropharmacology95: 243–251.
7.
BauerPONukinaN (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Journal of Neurochemistry110: 1737–1765.
8.
BennettJPJrEnnaSJBylundDB. (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry36: 927–934.
9.
Benoit-MarandMBorrelliEGononF (2001) Inhibition of dopamine release via presynaptic D2 receptors: Time course and functional characteristics in vivo. Journal of Neuroscience21: 9134–9141.
10.
BevinsRABesheerJ (2006) Object recognition in rats and mice: A one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nature Protocols1: 1306–1311.
11.
BraffDLGeyerMA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Archives of General Psychiatry47: 181–188.
12.
BuchmayerFSchickerKSteinkellnerT. (2013) Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proceedings of the National Academy of Sciences of the United States of America110: 11642–11647.
13.
BudsonAEPriceBH (2001) Memory: Clinical disorders. In Encyclopedia of Life Sciences. London: Macmillan Publishers Ltd, Nature Publishing Group.
14.
ChenCMLaneHYWuYR. (2005) Expanded trinucleotide repeats in the TBP/SCA17 gene mapped to chromosome 6q27 are associated with schizophrenia. Schizophrenia Research78: 131–136.
15.
ClaesSVan ZandKLegiusE. (1995) Correlations between triplet repeat expansion and clinical features in Huntington’s disease. Archives of Neurology52: 749–753.
16.
DereEHustonJPDe Souza SilvaMA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience Biobehavioral Reviews31: 673–704.
17.
Fusar-PoliPBonoldiIYungAR. (2012) Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry69: 220–229.
18.
Fusar-PoliPCappucciatiMBorgwardtS. (2016) Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification. JAMA Psychiatry73: 113–120.
19.
GaitondeEJSivagnanasundaramSMorrisAG. (1997) The number of triplet repeats in five brain-expressed loci with CAG repeats is not associated with schizophrenia. Schizophrenia Research25: 111–116.
20.
GreenTKHarveyJA (1974) Enhancement of amphetamine action after interruption of ascending serotonergic pathways. Journal of Pharmacology and Experimental Therapeutics190: 109–117.
21.
HolzmannCMauelerWPetersohnD. (1998) Isolation and characterization of the rat huntingtin promoter. Biochemical Journal336 (Pt 1): 227–234.
22.
HongKSWonHHChoEY. (2009) Genome-widely significant evidence of linkage of schizophrenia to chromosomes 2p24.3 and 6q27 in an SNP-based analysis of Korean families. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics150B: 647–652.
23.
HowesODKambeitzJKimE. (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry69: 776–786.
24.
HowesODKapurS (2014) A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry205: 1–3.
25.
HowesODMontgomeryAJAsselinMC. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry66: 13–20.
26.
JonesALMiddleFGuyC. (1997) No evidence for expanded polyglutamine sequences in bipolar disorder and schizophrenia. Molecular Psychiatry2: 478–482.
27.
KellyPHSeviourPWIversenSD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Research94: 507–522.
28.
KelpAKoeppenAHPetrasch-ParwezE. (2013) A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. Journal of Neuroscience33: 9068–9081.
29.
KimMNJutkiewiczEMZhangM. (2011) The sensitizing effect of acute nicotine on amphetamine-stimulated behavior and dopamine efflux requires activation of beta2 subunit-containing nicotinic acetylcholine receptors and glutamate N-methyl-D-aspartate receptors. Neuropharmacology60: 1126–1134.
30.
KohlSHeekerenKKlosterkotterJ. (2013) Prepulse inhibition in psychiatric disorders – apart from schizophrenia. Journal of Psychiatric Research47: 445–452.
31.
KoideRKobayashiSShimohataT. (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: A new polyglutamine disease?Human Molecular Genetics8: 2047–2053.
32.
LaruelleM (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Research. Brain Research Reviews31: 371–384.
33.
LightGASwerdlowNRRisslingAJ. (2012) Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One7: e39434.
34.
LuckiIHarveyJA (1979) Increased sensitivity to d- and l-amphetamine action after midbrain raphe lesions as measured by locomotor activity. Neuropharmacology18: 243–249.
35.
MoghaddamBAdamsBVermaA. (1997) Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience17: 2921–2927.
36.
MorrisAGGaitondeEMcKennaPJ. (1995) CAG repeat expansions and schizophrenia: Association with disease in females and with early age-at-onset. Human Molecular Genetics4: 1957–1961.
37.
MorteraPHerculano-HouzelS (2012) Age-related neuronal loss in the rat brain starts at the end of adolescence. Frontiers in Neuroanatomy6: 45.
38.
MullerCPPumMEAmatoD. (2011) The in vivo neurochemistry of the brain during general anesthesia. Journal of Neurochemistry119: 419–446.
39.
NeillDBGrantLDGrossmanSP (1972) Selective potentiation of locomotor effects of amphetamine by midbrain raphe lesions. Physiology & Behavior9: 655–657.
40.
NguyenHPKobbePRahneH. (2006) Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington’s disease. Human Molecular Genetics15: 3177–3194.
41.
NuechterleinKHDawsonME (1984) Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin10: 160–203.
42.
O’DonovanMCGuyCCraddockN. (1996) Confirmation of association between expanded CAG/CTG repeats and both schizophrenia and bipolar disorder. Psychological Medicine26: 1145–1153.
43.
OhiKHashimotoRYasudaY. (2009) TATA box-binding protein gene is associated with risk for schizophrenia, age at onset and prefrontal function. Genes, Brain, and Behavior8: 473–480.
44.
PaniLCarboniSKusminA. (1990) Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. European Journal of Pharmacology176: 245–246.
45.
PaxinosGWatsonC (1986) The Rat Brain in Stereotactic Coordinates. New York: Academic.
46.
PierceRCKalivasPW (1997) Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. Journal of Neuroscience17: 3254–3261.
47.
PumMCareyRJHustonJP. (2007) Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats. Psychopharmacology (Berl)193: 375–390.
48.
QuednowBBGeyerMAHalberstadtAL (2010) Serotonin and Schizophrenia. In: MüllerCPJacobsBL (eds) Handbook of the Behavioral Neurobiology of Serotonin. London: Academic Press, pp. 585–620.
49.
RalphRJPaulusMPFumagalliF. (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists. Journal of Neuroscience21: 305–313.
50.
Ralph-WilliamsRJLehmann-MastenVOtero-CorchonV. (2002) Differential effects of direct and indirect dopamine agonists on prepulse inhibition: A study in D1 and D2 receptor knock-out mice. Journal of Neuroscience22: 9604–9611.
51.
RasmussenHErritzoeDAndersenR. (2010) Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Archives of General Psychiatry67: 9–16.
52.
RileyBEOrrHT (2006) Polyglutamine neurodegenerative diseases and regulation of transcription: Assembling the puzzle. Genes & Development20: 2183–2192.
53.
RobinsonTEBeckerJB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Research396: 157–198.
54.
RolfsAKoeppenAHBauerI. (2003) Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Annals of Neurology54: 367–375.
55.
RubinszteinDCLeggoJCrowTJ. (1996) Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. American Journal of Medical Genetics67: 495–498.
56.
SarreSYuanHJonkersN. (2004) In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. Journal of Neurochemistry90: 29–39.
57.
ShahAJhawarSSGoelA (2012) Analysis of the anatomy of the Papez circuit and adjoining limbic system by fiber dissection techniques. Journal of Clinical Neuroscience19: 289–298.
58.
SimKDeWittIDitmanT. (2006) Hippocampal and parahippocampal volumes in schizophrenia: A structural MRI study. Schizophrenia Bulletin32: 332–340.
59.
SirugoGDeinardASKiddJR. (1997) Survey of maximum CTG/CAG repeat lengths in humans and non-human primates: Total genome scan in populations using the Repeat Expansion Detection method. Human Molecular Genetics6: 403–408.
60.
SnyderGLKellerRWJrZigmondMJ (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: Evidence for compensatory hyperactivity of residual terminals. Journal of Pharmacology and Experimental Therapeutics253: 867–876.
61.
SulzerDChenTKLauYY. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. Journal of Neuroscience15: 4102–4108.
62.
SwerdlowNRBraffDLGeyerMA (1990) GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Research532: 146–150.
63.
SwerdlowNRPaulsenJBraffDL. (1995) Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. Journal of Neurology, Neurosurgery, and Psychiatry58: 192–200.
64.
TsuangDAlmqvistEWLipeH. (2000) Familial aggregation of psychotic symptoms in Huntington’s disease. American Journal of Psychiatry157: 1955–1959.
65.
TsuangDDiGiacomoLLipeH. (1998) Familial aggregation of schizophrenia-like symptoms in Huntington’s disease. American Journal of Medical Genetics81: 323–327.
66.
TuretskyBIMobergPJRoalfDR. (2003) Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia. Archives of General Psychiatry60: 1193–1200.
67.
UrbachYKRaberKACannevaF. (2014) Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington’s disease. Journal of Neuroscience Methods234: 38–53.
68.
UrbachYKRaberKANguyenHP. (2009) Comprehensive classical and automated phenotyping reveals a schizophrenic-like, clozapine-responsive phenotype in a transgenic rat model for spinocerebellar ataxia (SCA17). EMBL Workshop on Translating Behaviour: Bridging Clinical and Animal Model Research, Heidelberg, Germany, 14–16 November 2009.
69.
van OsJKenisGRuttenBP (2010) The environment and schizophrenia. Nature468: 203–212.
70.
van Roon-MomWMReidSJFaullRL. (2005) TATA-binding protein in neurodegenerative disease. Neuroscience133: 863–872.
71.
von HorstenSSchmittINguyenHP. (2003) Transgenic rat model of Huntington’s disease. Human Molecular Genetics12: 617–624.
72.
YoungJWPowellSBRisbroughV. (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology & Therapeutics122: 150–202.
73.
ZappacostaBMonzaDMeoniC. (1996) Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington’s disease. Archives of Neurology53: 493–497.
74.
ZoghbiHYOrrHT (2000) Glutamine repeats and neurodegeneration. Annual Review of Neuroscience23: 217–247.
